この記事の翻訳を準備しています。それまでの間、英語の原文を表示します。
ビジネス · 2021/10/221 分で読めます
Fresenius USA, Inc., et al.; Withdrawal of Approval of 216 Abbreviated New Drug Applications
ローカル自動翻訳 · 情報源の原言語
概要
The Food and Drug Administration (FDA or Agency) is withdrawing approval of 216 abbreviated new drug applications (ANDAs) from multiple holders of those ANDAs. The basis for the withdrawal is that these ANDA holders have repeatedly failed to submit required annual reports for those ANDAs.
情報源の原言語: Federal Register — Food and Drug Administration原文の発表を開く →